- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03809845
Serial Fasciculation Measurements in Motor Neurone Disease
Sequential High-density Surface Electromyography (HDSEMG) Recordings in Motor Neurone Disease: Fasciculations as a Biomarker of Motor Neurone Health
Patients with motor neurone disease (MND) typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery.
Muscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. The investigators predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual.
In order to calibrate this technique, the investigators will conduct a 12-month longitudinal study, recruiting 24 patients from the King's College Hospital Motor Nerve Clinic, comprising a mixture of patients with MND and those with benign fasciculation syndrome. Patients in this latter group have fasciculations but do not develop weakness and have normal lifespans. They are therefore an optimal control group. At each visit, the investigators will take resting HDSEMG recordings from all four limbs and perform standard clinical measures of disease progression. The investigators will also monitor the decline in motor unit number using a newly validated neurophysiological technique, called Motor Unit Number Index (MUNIX).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- King's College Hospital NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria for MND patients:
(i) Aged between 40 and 80 years of age inclusive, at the time of signing the informed consent.
(ii) Diagnosed with MND by a neurologist with expertise in MND.(20) For subjects with bulbar onset there must be objective limb involvement of at least one limb.
(iii) Diagnosed with MND within 24 months of symptom onset. (iv) Subjects must be ambulatory (i.e. must not be confined to a wheelchair). (v) Male and female subjects (vi) Capable of giving signed informed consent (vii) Capable and willing to comply with the requirements of the protocol (either by themselves or with assistance).
Inclusion criteria for Benign Fasciculation Syndrome (BFS) patients:
(i) Aged between 18 and 80 years of age inclusive, at the time of signing the informed consent.
(ii) Diagnosed with BFS by a neurologist with expertise in motor nerve disorders.
(iii) Male and female subjects (vi) Capable of giving signed informed consent (vii) Capable and willing to comply with the requirements of the protocol (either by themselves or with assistance).
Exclusion criteria for MND patients:
(i) Neurological (other than the subject's MND) or non-neurological co-morbidities (e.g. joint disease, respiratory disease) which limit mobility.
(ii) Clinically significant cognitive impairment in the opinion of the investigator or lacking capacity in accordance with the Mental Capacity Act (2005).
(iii) Regionally restricted forms of MND, or other atypical variants:
- Isolated corticobulbar pattern of MND with normal ambulation
- Primary lateral sclerosis
- Signs of chronic partial denervation restricted to a single limb
MND or parkinsonism dementia complex (iv) Subjects requiring mechanical ventilation (non-invasive ventilation for sleep apnoea is allowed).
(v) Historical or current evidence of clinically significant uncontrolled disease which, in the opinion of the chief investigator, would put the safety of the subject at risk through participation or impact the study assessments or endpoints.
(vi) Presence of an active implantable cardiac medical device (e.g., pacemaker or implantable cardioverter-defibrillator) or at a high risk for needing external defibrillation.
(vii) History of skin hypersensitivity to adhesives. (viii) Current participation in a clinical trial which in the opinion of the chief investigator might impact the objectives of this study.
Exclusion criteria for Benign Fasciculation Syndrome patients:
(i) Significant diagnostic uncertainty, whereby motor neurone disease remains a possible differential diagnosis.
(ii) Historical or current evidence of clinically significant uncontrolled disease which, in the opinion of the chief investigator, would put the safety of the subject at risk through participation or impact the study assessments or endpoints.
(iii) Presence of an active implantable cardiac medical device (e.g., pacemaker or implantable cardioverter-defibrillator) or at a high risk for needing external defibrillation.
(iv) History of skin hypersensitivity to adhesives. (v) Current participation in a clinical trial which in the opinion of the chief investigator might impact the objectives of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Motor neuron disease
|
High-density surface electromyography
|
Active Comparator: Benign fasciculation syndrome
|
High-density surface electromyography
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fasciculation frequency over time
Time Frame: 12 months
|
To characterise the frequency of fasciculations in patients with motor neurone disease and to determine whether these parameters correlate with the trajectory of disease progression over a 12-month period.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fasciculation morphology over time
Time Frame: 12 months
|
12 months
|
|
Change in Functional Rating Scale (FRS) over time
Time Frame: 12 months
|
Maximum score of 48; lower scores indicate worse disability
|
12 months
|
Change in motor unit number index measurements over time
Time Frame: 12 months
|
12 months
|
|
Change in MRC power sum score over time
Time Frame: 12 months
|
12 months
|
|
Change in slow vital capacity over time
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Neuromuscular Diseases
- Fasciculation
Other Study ID Numbers
- KCH17-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motor Neuron Disease
-
University of EdinburghUniversity College, London; NHS Lothian; University of WarwickRecruitingMotor Neuron Disease, Amyotrophic Lateral SclerosisUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingProgressive Motor Neuron Disease Without Definite Diagnosis
-
Hospital for Special Surgery, New YorkActive, not recruiting
-
National Institute of Neurological Disorders and...Completed
-
Liverpool University Hospitals NHS Foundation TrustNot yet recruitingMotor Neuron Disease, Amyotrophic Lateral Sclerosis
-
Bioinova, s.r.o.Department of Neurology, University Hospital Motol, Prague, Czech RepublicCompletedMotor Neuron Disease, Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineEnrolling by invitationMotor Neuron Disease | Amyotrophic Lateral Sclerosis | Lou Gehrig Disease | Familial Amyotrophic Lateral Sclerosis | Motor Neuron Disease, FamilialUnited States
-
Ambulanzpartner Soziotechnologie APST GmbHCharite University, Berlin, GermanyRecruitingMotor Neuron Disease, Amyotrophic Lateral SclerosisGermany
-
Ottawa Hospital Research InstituteRecruitingTetraplegia | Motor Neuron Disease, Amyotrophic Lateral SclerosisCanada
-
MedRegen LLCNot yet recruitingMotor Neuron Disease | Amyotrophic Lateral Sclerosis | Lou Gehrig Disease | Motor Neuron Atrophy
Clinical Trials on High-density surface electromyography
-
University of Dublin, Trinity CollegeMotor Neurone Disease Association, UK; Irish Research Council, IE; Research Motor... and other collaboratorsRecruitingALS (Amyotrophic Lateral Sclerosis) | Postpoliomyelitis Syndrome | Spinal Muscular AtrophyIreland
-
Assistance Publique - Hôpitaux de ParisUniversité de Technologie de CompiegneCompletedHip Fracture, Post Surgery Recovery, Muscle ResilienceFrance
-
Assistance Publique - Hôpitaux de ParisSorbonne University; Université de Technologie de CompiegneCompleted
-
University of MalayaCompleted
-
University of Castilla-La ManchaUniversity of AlcalaCompleted
-
Sheba Medical CenterUnknownWork Related Musculoskeletal DisordersIsrael
-
University of HaifaUnknown
-
University of Southern CaliforniaCompletedCerebral Palsy | Dystonia | Spasticity | Hypertonia | RigidityUnited States
-
Weill Medical College of Cornell UniversityNot yet recruitingDysphonia | AphoniaUnited States
-
Universidad Católica San Antonio de MurciaCompletedStroke, ComplicationSpain